Zafirlukast is a medication used in the management and treatment of chronic asthma. It is in the leukotriene receptor antagonist (LTRA) class. Zafirlukast is available as 10 mg and 20 mg tablets and chewable tablets, which are FDA-approved for managing chronic asthma in adults and children five years and older. It is used off-label in managing chronic urticaria, preventing exercise-induced bronchospasm, and allergic rhinitis. According to the GINA (Global Initiative for Asthma) guidelines, LTRA (montelukast or zafirlukast) is an essential controller therapy for patients unable to tolerate ICS inhaled corticosteroids. This activity reviews the indications, action, and contraindications for zafirlukast as an agent in the management and prophylaxis of chronic asthma. In addition, this activity will highlight the mechanism of action, adverse event profile, and other vital factors pertinent to the care of patients with chronic asthma.

**Objectives:**
- Identify the mechanism of action of zafirlukast.
- Describe the possible adverse effects of zafirlukast.
- Review the appropriate monitoring for patients using zafirlukast.
- Summarize interprofessional team strategies for improving care coordination and communication to advance the proper usage of zafirlukast and improve outcomes.